Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ)
CNY 18.84
(0.48%)
CNY 18.84
(0.48%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 9.79 Billion CNY | -0.75% |
| 2022 | 9.08 Billion CNY | -23.87% |
| 2021 | 12.39 Billion CNY | 197.47% |
| 2020 | 4.1 Billion CNY | 40.74% |
| 2019 | 2.93 Billion CNY | 60.67% |
| 2018 | 1.8 Billion CNY | 202.65% |
| 2017 | 574.66 Million CNY | 381.48% |
| 2016 | 91.27 Million CNY | -54.2% |
| 2015 | 272.91 Million CNY | 27.62% |
| 2014 | 210.7 Million CNY | -3.66% |
| 2013 | 187.51 Million CNY | 9.46% |
| 2012 | 204.17 Million CNY | -18.47% |
| 2011 | 249.08 Million CNY | -20.19% |
| 2010 | 318.1 Million CNY | 16.67% |
| 2009 | 260.83 Million CNY | 16.77% |
| 2008 | 231.22 Million CNY | 23.83% |
| 2007 | 190.19 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -60.26 Million CNY | -106.25% |
| 2024 Q2 | 952.57 Million CNY | -46.87% |
| 2024 Q1 | 2.1 Billion CNY | -0.95% |
| 2023 Q2 | 2.74 Billion CNY | 5.45% |
| 2023 Q3 | 2.97 Billion CNY | 8.68% |
| 2023 Q4 | 1.81 Billion CNY | -39.1% |
| 2023 FY | - CNY | -0.75% |
| 2023 Q1 | 2.59 Billion CNY | 4.34% |
| 2022 Q2 | 2.21 Billion CNY | -7.03% |
| 2022 Q3 | 2.22 Billion CNY | 0.46% |
| 2022 Q4 | 2.49 Billion CNY | 12.1% |
| 2022 FY | - CNY | -23.87% |
| 2022 Q1 | 2.37 Billion CNY | 6.8% |
| 2021 Q1 | 1.19 Billion CNY | 24.9% |
| 2021 Q3 | 3.47 Billion CNY | -35.04% |
| 2021 Q4 | 2.22 Billion CNY | -36.0% |
| 2021 FY | - CNY | 197.47% |
| 2021 Q2 | 5.35 Billion CNY | 348.9% |
| 2020 Q3 | 1.16 Billion CNY | -10.52% |
| 2020 Q2 | 1.29 Billion CNY | 82.27% |
| 2020 Q1 | 711.81 Million CNY | -2.26% |
| 2020 FY | - CNY | 40.74% |
| 2020 Q4 | 955.36 Million CNY | -17.71% |
| 2019 Q4 | 728.24 Million CNY | -5.64% |
| 2019 FY | - CNY | 60.67% |
| 2019 Q3 | 771.74 Million CNY | -3.0% |
| 2019 Q2 | 795.6 Million CNY | 25.65% |
| 2019 Q1 | 633.18 Million CNY | 32.24% |
| 2018 Q2 | 494.27 Million CNY | 52.1% |
| 2018 Q3 | 494.96 Million CNY | 0.14% |
| 2018 FY | - CNY | 202.65% |
| 2018 Q1 | 324.97 Million CNY | 92.37% |
| 2018 Q4 | 478.83 Million CNY | -3.26% |
| 2017 Q4 | 168.93 Million CNY | 18.9% |
| 2017 Q3 | 142.07 Million CNY | 0.57% |
| 2017 FY | - CNY | 381.48% |
| 2017 Q1 | 90.83 Million CNY | 271.16% |
| 2017 Q2 | 141.26 Million CNY | 55.52% |
| 2016 FY | - CNY | -54.2% |
| 2016 Q4 | 24.47 Million CNY | 304.62% |
| 2016 Q3 | 6.04 Million CNY | 113.12% |
| 2016 Q2 | -46.08 Million CNY | -157.63% |
| 2016 Q1 | 79.95 Million CNY | 47.63% |
| 2015 Q3 | 59.29 Million CNY | -24.78% |
| 2015 Q4 | 54.16 Million CNY | -8.65% |
| 2015 FY | - CNY | 27.62% |
| 2015 Q1 | 56.02 Million CNY | 181.58% |
| 2015 Q2 | 78.82 Million CNY | 40.71% |
| 2014 Q3 | 44.32 Million CNY | -39.4% |
| 2014 FY | - CNY | -3.66% |
| 2014 Q1 | 50.77 Million CNY | -6.38% |
| 2014 Q2 | 73.13 Million CNY | 44.04% |
| 2014 Q4 | 19.89 Million CNY | -55.11% |
| 2013 Q3 | 32.21 Million CNY | -54.53% |
| 2013 FY | - CNY | 9.46% |
| 2013 Q1 | 46.52 Million CNY | -35.31% |
| 2013 Q2 | 70.83 Million CNY | 52.25% |
| 2013 Q4 | 54.23 Million CNY | 68.38% |
| 2012 Q1 | 39.99 Million CNY | -60.16% |
| 2012 FY | - CNY | -18.47% |
| 2012 Q2 | 43.59 Million CNY | 9.0% |
| 2012 Q3 | 31.68 Million CNY | -27.32% |
| 2012 Q4 | 71.91 Million CNY | 127.0% |
| 2011 Q4 | 100.39 Million CNY | 304.6% |
| 2011 Q3 | 24.81 Million CNY | -73.12% |
| 2011 Q2 | 92.3 Million CNY | 197.51% |
| 2011 Q1 | 31.02 Million CNY | -71.23% |
| 2011 FY | - CNY | -20.19% |
| 2010 Q3 | 44.35 Million CNY | -64.81% |
| 2010 Q2 | 126.05 Million CNY | 322.59% |
| 2010 Q1 | 29.82 Million CNY | -65.88% |
| 2010 FY | - CNY | 16.67% |
| 2010 Q4 | 107.82 Million CNY | 143.08% |
| 2009 Q4 | 87.41 Million CNY | 86.1% |
| 2009 Q3 | 46.96 Million CNY | 0.0% |
| 2009 FY | - CNY | 16.77% |
| 2008 FY | - CNY | 23.83% |
| 2007 FY | - CNY | 0.0% |